- Home
- NVRI vs AVXL Comparison
NVRI vs AVXL Comparison
Compare NVRI & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- AVXL
- Stock Information
- Founded
- NVRI 1853
- AVXL 2004
- Country
- NVRI United States
- AVXL United States
- Employees
- NVRI N/A
- AVXL N/A
- Industry
- NVRI Diversified Commercial Services
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVRI Miscellaneous
- AVXL Health Care
- Exchange
- NVRI Nasdaq
- AVXL Nasdaq
- Market Cap
- NVRI 911.3M
- AVXL 956.7M
- IPO Year
- NVRI N/A
- AVXL N/A
- Fundamental
- Price
- NVRI $12.46
- AVXL $8.67
- Analyst Decision
- NVRI Hold
- AVXL Strong Buy
- Analyst Count
- NVRI 1
- AVXL 2
- Target Price
- NVRI $10.00
- AVXL $44.00
- AVG Volume (30 Days)
- NVRI 1.3M
- AVXL 968.2K
- Earning Date
- NVRI 10-30-2025
- AVXL 08-12-2025
- Dividend Yield
- NVRI N/A
- AVXL N/A
- EPS Growth
- NVRI N/A
- AVXL N/A
- EPS
- NVRI N/A
- AVXL N/A
- Revenue
- NVRI $2,242,873,000.00
- AVXL N/A
- Revenue This Year
- NVRI N/A
- AVXL N/A
- Revenue Next Year
- NVRI $3.72
- AVXL N/A
- P/E Ratio
- NVRI N/A
- AVXL N/A
- Revenue Growth
- NVRI N/A
- AVXL N/A
- 52 Week Low
- NVRI $4.72
- AVXL $5.03
- 52 Week High
- NVRI $12.84
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- NVRI 74.64
- AVXL 38.75
- Support Level
- NVRI $12.07
- AVXL $8.85
- Resistance Level
- NVRI $11.97
- AVXL $9.69
- Average True Range (ATR)
- NVRI 0.40
- AVXL 0.55
- MACD
- NVRI 0.03
- AVXL -0.04
- Stochastic Oscillator
- NVRI 81.28
- AVXL 6.49
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.